Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-4285 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-4285 | EXPERIMENTAL | Participants will be administered ALN-4285 subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered placebo SC |
| Name | Type | Description |
|---|---|---|
| ALN-4285 | DRUG | ALN-4285 will be administered SC |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Has a body mass index (BMI) of ≥18.0 kg/m\^2 and ≤30 kg/m\^2 * Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)...
ALN-4285 is an investigational small molecule therapeutic being developed by Alnylam Pharmaceuticals, Inc. It is currently in Phase 1 clinical development and is being studied in healthy adult volunteers. Its specific disease indications have not been disclosed.
ALN-4285 is being developed by Alnylam Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ALNY. Alnylam is the sponsor of the clinical program evaluating this investigational small molecule therapeutic.
ALN-4285 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 study is enrolling healthy adult volunteers to evaluate the drug.
ALN-4285 is being evaluated in one clinical trial, NCT07295717, titled A Study to Evaluate ALN-4285 in Adult Healthy Volunteers. This Phase 1 trial is currently recruiting, is placebo-controlled and double-blind, and plans to enroll 76 participants in the United Kingdom.
The Phase 1 trial NCT07295717 is enrolling healthy adult volunteers aged 18 years and older, with no restriction by sex. The study is being conducted in the United Kingdom and is currently recruiting participants.
No. ALN-4285 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. It is being studied in healthy volunteers under clinical trial NCT07295717, which is currently recruiting.